American Capital Advisory’s Vaxcyte PCVX Stock Holding History

American Capital Advisory’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59	Hold	1	–	–	﹤0.01%	1150
2026 Q1	$59	Buy	+1	New	+$54	﹤0.01%	1125

Other funds holding PCVX

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

BAAM

Baker Avenue Asset Management San Francisco, California $5.28B AUM 39.19% 1-Year Est. Return

SLAM

Swiss Life Asset Management Zurich $24.1B AUM 38.82% 1-Year Est. Return

MGWM

Marks Group Wealth Management Minnetonka, Minnesota $1.15B AUM 16.94% 1-Year Est. Return

American Capital Advisory's PCVX Position: Q2 2026 in Review

American Capital Advisory held its Vaxcyte (PCVX) position steady in Q2 2026 at 1 share worth $59. The position accounts for ﹤0.01% of the portfolio, ranked #1150.

American Capital Advisory first reported a position in PCVX in Q1 2026 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

American Capital Advisory held 1 share of Vaxcyte worth $59 as of Q2 2026.
American Capital Advisory left its Vaxcyte share count unchanged in Q2 2026.
Vaxcyte made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #1150 holding.
American Capital Advisory first reported a position in Vaxcyte in Q1 2026 and has held it in 2 quarters since.
54 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.